CVRX at a glance
CVRx, Inc. (CVRX, SEC CIK 1235912) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 21, 2026 and Form 4 insider filings as recently as August 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), CVRx, Inc. (CVRX) reported revenue of $56.7 million (up 10.4% from FY2024) and a net loss of $53.3 million. Diluted EPS was -$2.04.
- As of June 30, 2026, 22 institutional investment managers tracked by SignalX reported holding CVRx, Inc. (CVRX) shares worth $40.5 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by Binkowski Brent on August 13, 2026 of 26,223 shares at $2.91 per share.
- In the last 90 days, CVRX insiders reported 1 open-market purchase ($76K) and 1 open-market sale ($3K) on Form 4, a net purchase of $73K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $56.7M
- +10.4% vs prior year
- Insiders · 90 days
- 1 buy · 1 sell
- Net +$73K
- 13F holders
- 22 funds
- $40.5M · −1 vs prior quarter
- Latest 8-K
- Sep 21, 2026
- Item 5.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Management Discussion & Analysis
- Q2 revenue $15.7M, up 16% YoY from $13.6M
- Gross margin 87% vs 84% YoY; operating loss $13.0M vs $14.4M
- U.S. revenue $14.8M, up 21%; Europe weakest at $0.9M, down 31%
- Cash $64.6M vs $75.7M at December 31; six-month operating cash use $21.0M
- Second-half growth expected lower; headwinds from fewer territories, productivity, and payer challenges
Risk Factors
- No risk-factors section provided; supplied text covers Items 2–6 and signatures only
- No newly added or materially updated risk identified
- No regulatory, legal, compliance, operational, competitive, market, or financial risks disclosed in provided text
AI summary of the CVRX 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 5.02: Departure/Appointment of Directors or Principal Officers
- John Landry appointed CFO effective after CVRx files its September 30, 2026 Form 10-Q
- Succeeds Jared Oasheim, whose previously announced resignation awaits successor transition
Item EX-99.1: Item EX-99.1
- John Landry appointed CFO, succeeding Jared Oasheim after his previously announced resignation
- Landry joins October 12, 2026 and assumes CFO duties after CVRx files its September 30, 2026 Form 10-Q
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Chief Revenue Officer Robert John departed CVRx effective August 10, 2026
- Termination triggers severance pay and benefits under his employment agreement, subject to contractual conditions
Item EX-99.1: Item EX-99.1
- Chief Revenue Officer Robert John departing; Paul Verrasto appointed Interim Head of Sales effective immediately
- Leadership change driven by revised commercial outlook and need to improve commercial execution
Item 2.02: Results of Operations and Financial Condition
- Item 2.02 furnishing disclaimer only, without operating or financial results
- Information not deemed filed under Exchange Act Section 18
Item EX-99.1: Item EX-99.1
- Q2 revenue $15.7M, up 16%; U.S. revenue $14.8M, up 21%, indicating continued Barostim adoption
- U.S. revenue units rose to 466 from 391; active implanting centers reached 258 from 240
AI summaries of CVRX 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for CVRX
Don't miss the next CVRX filing
- Alerts as it files. A push when CVRX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut CVRX, by share count.
- Ask anything. An AI agent that reads every CVRX filing and answers with sources.
CVRX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Binkowski Brent | Buy | Aug 13, 2026 | 26,223 | $2.91 |
| Binkowski Brent | Sell | Aug 12, 2026 | 1,309 | $2.55 |
| Nielsen Kirk G. | A | Jun 1, 2026 | 11,182 | - |
| SHADAN MARTHA | A | Jun 1, 2026 | 8,720 | - |
| Jain Mudit K. | A | Jun 1, 2026 | 8,720 | - |
| Jain Mudit K. | A | Jun 1, 2026 | 11,182 | - |
| Ballinger Kevin J. | A | Jun 1, 2026 | 11,182 | - |
| Ballinger Kevin J. | A | Jun 1, 2026 | 8,720 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $51.3M | $56.7M |
| Gross Profit | - | $43.0M | $48.3M |
| Operating Income | - | -$59.5M | -$51.3M |
| Net Income | - | -$60.0M | -$53.3M |
| Gross Margin | - | 83.8% | 85.3% |
| Op. Margin | - | -116.0% | -90.5% |
| Net Margin | - | -116.9% | -94.1% |
| Balance Sheet | |||
| Total Assets | $115.2M | $133.4M | $104.8M |
| Equity | $75.9M | $71.1M | $39.3M |
| ROE | - | -84.4% | -135.6% |
| Per Share | |||
| EPS | - | $-2.65 | $-2.04 |
| Cash Flow | |||
| Operating CF | - | -$39.1M | -$40.2M |
| CapEx | - | $1.4M | $580K |
Source: XBRL data in CVRx, Inc. (CVRX)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate CVRX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 22 | $40.5M |
| Q1 2026 | 23 | $69.3M |
| Q4 2025 | 19 | $56.5M |
| Q3 2025 | 20 | $65.5M |
| Q2 2025 | 21 | $46.5M |
| Q1 2025 | 18 | $86.2M |
| Q4 2024 | 14 | $77.7M |
| Q3 2024 | 11 | $46.1M |
- BlackRock+218.9K (+21%)
- Renaissance Technologies LLC+210.7K (+1092%)
- Dimensional Fund Advisors+75.3K (+143%)
- Citadel Advisors LLC+52.4K (+197%)
- Two Sigma Investments+18.2K (+16%)
- Goldman Sachs Group−51.5K (-26%)
- Northern Trust−25.4K (-17%)
- Bank of America Corp−11.1K (-36%)
- FMR LLC (Fidelity)−1.8K (-84%)
- Vanguard Capital Management LLC−734 (-0%)
- D.E. Shaw & Co−11.2K
Source: 13F-HR filings on SEC EDGAR (aggregated from 148 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
CVRX filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 21, 2026 | - | Analysis | - |
| SC 13D | Aug 24, 2026 | - | - | |
| SC 13G | Aug 14, 2026 | - | - | |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Jun 9, 2026 | - | Analysis | |
| 8-K | Jun 3, 2026 | - | Analysis | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 4 | Jun 3, 2026 | - | - | |
| 10-Q | May 12, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | May 11, 2026 | - | Analysis | |
| 8-K | Apr 13, 2026 | - | Analysis | - |
| 4 | Mar 16, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 8-K | Mar 3, 2026 | - | Analysis | - |
| 4 | Mar 3, 2026 | - | - | - |
| 4 | Mar 3, 2026 | - | - | - |
| 10-K | Feb 13, 2026 | Dec 31, 2025 | - |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
CVRX SEC filings: frequently asked questions
Are CVRX insiders buying or selling?
In the last 90 days, CVRx, Inc. (CVRX) officers, directors and 10% owners reported 1 open-market purchase worth $76,432 by 1 insider and 1 open-market sale worth $3,338 by 1 insider on Form 4, a net purchase of $73,094. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold CVRX stock?
As of June 30, 2026, the largest CVRx, Inc. (CVRX) holders among the 13F filers tracked by SignalX were Johnson & Johnson ($20.7 million), BlackRock ($6.4 million), Vanguard Capital Management LLC ($4.7 million), State Street Corp ($1.9 million), Renaissance Technologies LLC ($1.2 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was CVRX's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), CVRx, Inc. (CVRX) reported revenue of $56.7 million (up 10.4% from FY2024) and a net loss of $53.3 million. Diluted EPS was -$2.04. The figures come from the XBRL data in the 10-K.
What did CVRX report in its latest 8-K?
CVRx, Inc. (CVRX) filed an 8-K on September 21, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). John Landry appointed CFO effective after CVRx files its September 30, 2026 Form 10-Q.
What are the latest CVRX SEC filings?
CVRx, Inc. (CVRX) filed its latest 10-K annual report on February 13, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 21, 2026 and a Form 4 insider filing on August 13, 2026.
What is CVRX's SEC CIK number?
CVRx, Inc. (CVRX)'s SEC Central Index Key (CIK) is 1235912. EDGAR lists every CVRX filing under that number.
Ask anything about CVRX
The research agent reads CVRX's filings, financials, insider trades and 13F holders, then answers with sources.